Your browser doesn't support javascript.
loading
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.
Miglis, Mitchell G; Adler, Charles H; Antelmi, Elena; Arnaldi, Dario; Baldelli, Luca; Boeve, Bradley F; Cesari, Matteo; Dall'Antonia, Irene; Diederich, Nico J; Doppler, Kathrin; Dusek, Petr; Ferri, Raffaele; Gagnon, Jean-François; Gan-Or, Ziv; Hermann, Wiebke; Högl, Birgit; Hu, Michele T; Iranzo, Alex; Janzen, Annette; Kuzkina, Anastasia; Lee, Jee-Young; Leenders, Klaus L; Lewis, Simon J G; Liguori, Claudio; Liu, Jun; Lo, Christine; Ehgoetz Martens, Kaylena A; Nepozitek, Jiri; Plazzi, Giuseppe; Provini, Federica; Puligheddu, Monica; Rolinski, Michal; Rusz, Jan; Stefani, Ambra; Summers, Rebekah L S; Yoo, Dallah; Zitser, Jennifer; Oertel, Wolfgang H.
Affiliation
  • Miglis MG; Department of Neurology and Neurological Sciences and Department of Psychiatry and Behavioral Science, Stanford University, Palo Alto, CA, USA. Electronic address: mmiglis@stanford.edu.
  • Adler CH; Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA.
  • Antelmi E; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
  • Arnaldi D; Clinical Neurology, DINOGMI, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Baldelli L; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
  • Boeve BF; Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, MN, USA.
  • Cesari M; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Dall'Antonia I; Department of Neurology and Center of Clinical Neuroscience, Charles University First Faculty of Medicine, Prague, Czech Republic.
  • Diederich NJ; Department of Neuroscience, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg.
  • Doppler K; Department of Neurology, University of Würzburg, Würzburg, Germany.
  • Dusek P; Department of Neurology and Center of Clinical Neuroscience, Charles University First Faculty of Medicine, Prague, Czech Republic.
  • Ferri R; Oasi Research Institute IRCCS, Troina, Italy.
  • Gagnon JF; Centre for Advanced Research in Sleep Medicine, Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal-Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada.
  • Gan-Or Z; The Neuro-Montreal Neurological Institute-Hospital, Department of Neurology and Neurosurgery, and Department of Human Genetics, McGill University, Montreal, QC, Canada.
  • Hermann W; Department of Neurology, University of Rostock, Rostock, Germany; German Center for Neurodegenerative Diseases (DZNE), Research Site Rostock, Rostock, Germany.
  • Högl B; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Hu MT; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Iranzo A; Sleep Disorders Center, Neurology Service, Hospital Clínic Barcelona, Universitat de Barcelona, Barcelona, Spain.
  • Janzen A; Department of Neurology and Section on Clinical Neuroscience, Philipps University Marburg, Marburg, Germany.
  • Kuzkina A; Department of Neurology, University of Würzburg, Würzburg, Germany.
  • Lee JY; Department of Neurology, Seoul National University College of Medicine, Seoul, South Korea.
  • Leenders KL; Department of Nuclear Medicine and Biomedical Imaging, University Medical Center Groningen, Groningen, Netherlands.
  • Lewis SJG; ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.
  • Liguori C; Sleep Medicine Center, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Liu J; Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Lo C; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Ehgoetz Martens KA; Department of Kinesiology, Faculty of Applied Health Sciences, University of Waterloo, Waterloo, ON, Canada.
  • Nepozitek J; Department of Neurology and Center of Clinical Neuroscience, Charles University First Faculty of Medicine, Prague, Czech Republic.
  • Plazzi G; IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Provini F; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; UOC Clinica Neurologica Rete Metropolitana NEUROMET, Bellaria Hospital, Bologna, Italy.
  • Puligheddu M; Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
  • Rolinski M; Institute of Clinical Neurosciences, University of Bristol, Bristol, UK.
  • Rusz J; Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic.
  • Stefani A; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Summers RLS; Department of Neurology, University of Minnesota, Minneapolis, MN, USA.
  • Yoo D; Department of Neurology, Kyung Hee University Hospital, Seoul, South Korea.
  • Zitser J; Department of Neurology and Neurological Sciences, University of California, San Francisco, CA, USA; Department of Neurology, Tel Aviv Sourasky Medical Center, Affiliate of Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Oertel WH; Department of Neurology and Section on Clinical Neuroscience, Philipps University Marburg, Marburg, Germany; Institute for Neurogenomics, Helmholtz Center for Health and Environment, München-Neuherberg, Germany.
Lancet Neurol ; 20(8): 671-684, 2021 08.
Article in En | MEDLINE | ID: mdl-34302789
ABSTRACT
Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / REM Sleep Behavior Disorder / Synucleinopathies Type of study: Etiology_studies / Prognostic_studies Limits: Humans Language: En Journal: Lancet Neurol Journal subject: NEUROLOGIA Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / REM Sleep Behavior Disorder / Synucleinopathies Type of study: Etiology_studies / Prognostic_studies Limits: Humans Language: En Journal: Lancet Neurol Journal subject: NEUROLOGIA Year: 2021 Document type: Article